4 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 10 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Active not recruiting 2, Recruiting 2, Terminated 2 |
| Phase 1 | 5 | Completed 3, Active not recruiting 2 |
Follow Refractory Marginal Zone Lymphoma: new trials by email Literature Review of Refractory Marginal Zone Lymphoma trials Research Report on Refractory Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma CD47 Antagonist ALX148, Lenalidomide, Rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2021-10-13 | 2026-09-18 |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma Carfilzomib, Laboratory Biomarker Analysis, Rituximab - Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 2 | Terminated | University of Washington | 4 | 2017-12-18 | 2020-01-18 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2014-05-27 | 2025-06-24 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2011-07-20 | 2021-10-04 |
Lymphoma, B-Cell, Marginal Zone (10) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Non-Hodgkin (5) · Lymphoma, B-Cell (2) · Waldenstrom Macroglobulinemia (2) · Burkitt Lymphoma (1) · Composite Lymphoma (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphoid (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoma (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Lymphoma, B-Cell (8) · Disease Attributes (7) · Hematologic Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Chronic Disease (6) · Leukemia (6)
CT-P10 (4) · Rituximab (4) · Cyclophosphamide (3) · Cytarabine (2) · Dexamethasone (2) · Lenalidomide (2) · Stem Cell Transplantation (2) · venetoclax (2) · ALX148 (1) · Bortezomib (1) · Calcium Dobesilate (1) · Carmustine (1) · Cyclosporine (1) · Cyclosporins (1) · Etoposide (1)
Fred Hutchinson Cancer Center (2) · M.D. Anderson Cancer Center (2) · University of Washington (2) · Academic and Community Cancer Research United (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1) · Vanderbilt-Ingram Cancer Center (1)
United States (10)
Bhagirathbhai Dholaria (1) · Catherine S Diefenbach (1) · Kami Maddocks, MD (1) · Leonard T Heffner (1) · Loretta Nastoupil (1) · Mazyar Shadman (1) · Paolo Strati, MD (1) · Phuong Vo, MD (1) · Rahul Banerjee, MD (1) · Stephen Smith (1)
PMID 34515338, PMID 39161543, PMID 39319495
P30CA015083 (1), P30CA015704 (1), U10CA021115 (1), U10CA180820 (1)